Synthetic Lethal Interactions in Cancer Therapy

Author(s): Xinwei Geng, Xiaohui Wang, Dan Zhu*, Songmin Ying*.

Journal Name: Current Cancer Drug Targets

Volume 17 , Issue 4 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Silencing of two or more complementary signaling pathways can lead to cell death, while loss of any single genetic function does not show a severe phnotype, this kind of inter action is coined as “synthetic lethality”. Nowadays, synthetic lethality has become a widely used anti-cancer strategy.

Method: We reviewed the synthetic lethal interactions exploited in anticancer therapies before 2016.

Conclusion: Synthetic lethality is a well proved anticancer strategy and more synthetic lethal interactions is being translated into clinical cancer therapies.

Keywords: Synthetic lethality, targeted therapy, PARP inhibitors, drug resistance, cancer therapy, signaling pathways.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 4
Year: 2017
Page: [304 - 310]
Pages: 7
DOI: 10.2174/1568009616666160426122736
Price: $65

Article Metrics

PDF: 52
HTML: 7
EPUB: 1